FMX103 for Rosacea

[Guide]

According to a No Camels News Flash, Foamix Pharmaceuticals received approval for its product that treats Rosacea, FMX 103 for Rosacea. In a deal with Bayer, Foamix may receive $10 million US Dollars.

Hilltop News

Oppenheimer Equity Research Quarterly Update August 21, 2016

Foamix Announces Enrollment of First Patient in Phase 2 Clinical Trial of FMX103 in Papulopustular Rosacea

Sacks: Foamix Starts Patient Enrollment in Phase II Study on FMX103 

Foamix Pharmaceuticals Ltd., NY Times

Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea (EMIRA)

Foamix’s FMX103 meets efficacy endpoints in phase 2 trial for papulopustular rosacea

Foamix shares bubble up on Phase 2 data

September 10, 2016
Foamix to Announce Topline Results in Phase 2 Clinical Trial of FMX-103 Minocycline Topical Foam for Moderate-to-Severe Papulopustular Rosacea

September 12, 2016

“We are extremely encouraged that our Phase 2 dose-finding study demonstrated that FMX103 appears to be safe and effective in the treatment of moderate-to-severe papulopustular rosacea,” said Dov Tamarkin, Ph.D., CEO of Foamix. “We believe the positive data from our clinical trial could support advancement into Phase 3, and look forward to reviewing these results with the FDA.  Our goal is to bring innovative therapies to market in order to address the unmet needs of patients suffering from various dermatological conditions.  Based on our current results, FMX103 has the potential to provide significant benefits to the millions of patients who currently struggle with the physical effects of rosacea and the quality of life impact inherent with this disease.” Drug Discovery 

“We believe the positive data from our clinical trial could support advancement into phase 3, and look forward to reviewing these results with the FDA,” Dov Tamarkin, PhD, CEO of Foamix, stated in the release

FMX103 meets efficacy endpoints in treating papulopustular rosacea

October 20, 2015
http://www.benzinga.com/news/15/10/5927077/foamix-announces-enrollment-of-first-patient-in-phase-2-clinical-trial-of-fmx103-

December 1, 2016
Foamix to Host Key Opinion Leader Luncheon for Investors Focused on Dermatology, With a Focus on Acne and Rosacea
Meeting and Live Webcast on Friday, December 2, at 12 pm Eastern Time

Keynote presentations by Guy Webster, MD, PhD and Linda Stein Gold, MD (RRDi MAC Member)
Overview of FMX101, a novel minocycline foam for the treatment of moderate-to-severe acne, and FMX103 for the treatment of moderate-to-severe rosacea.

[Guide]

"The initiation of this Phase 3 program marks an important milestone for Foamix's FMX103 and it moves us closer to our goal of providing an effective and convenient new treatment for the millions of patients suffering from moderate-to-severe rosacea," stated Dr. Dov Tamarkin, CEO of Foamix.   "The design and clinical endpoints for this Phase 3 program are based on the results of our Phase 2 study, which was conducted in Germany with 233 rosacea patients, and our recent end-of-phase 2 meeting with the FDA. We expect topline data in mid-2018."

Foamix Announces Dosing of First Patient in Phase 3 Rosacea Clinical Trials for FMX103 Minocycline Foam 1.5%, PRNewswire

Foamix announces dosing of first patient in phase 3 rosacea clinical trials for FMX103 minocycline foam 1.5%
Foamix Pharmaceuticals Ltd - "we expect topline data in mid-2018" 
BRIEF-Foamix announces dosing of first patient in phase 3 rosacea clinical trials, Reuters

This thread is continued in the following thread:

Foamix Pharmaceuticals Topical Antibiotic Foam